........................................................................ 25
V
......................................................................... 29
.............................................................................. 31
NOODOPROEPEN .................................................................... 34
......................................................................... 35
........................................................................... 37
........................................................................ 39
-
(TOT) ............................................................... 40
N-iv
) ................................................. 24
..................................................................... 27
..................................................................... 27
............................................................... 28
.................................................................. 31
................................................................. 34
........................................................... 35
.............................................................. 36
.................................................................. 38
............................................................... 38
(BCL) ..................................................... 40
.................................................................... 40
............................................................. 41
) ........................... 28
) ............................. 30
............................................. 37
........................................... 41
) .................. 31